CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering. The offering priced 12,535,000 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,635,000 additional shares of common stock, at $17.00 per share for gross proceeds of approximately $213.1 million, before deducting underwriting discounts, commissions, and offering expenses. The shares began trading on September 15, 2022, and the offering closed on September 19, 2022.
Third Harmonic Bio is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation. The company’s lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. THB001 is currently being evaluated in a Phase 1b proof-of-concept study in chronic inducible urticaria. With promising drug-like properties and an encouraging early clinical profile, THB001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell-mediated inflammatory diseases.
The CFGI team was led by our Life Sciences and Capital Markets team members Ryan Dolan, Kelly Provost, and Erica Devlin.
For further information on the offering, please read Third Harmonic Bio’s press release.